Susanne Dr. Stowasser
Associate Head of Medicine TA Inflammation Boehringer Ingelheim
Dr. Stowasser is Associate Head of Medicine, Pulmonology at Boehringer Ingelheim, where she leads global clinical development and medical affairs efforts across early- to late-stage assets, including the potential new IPF/PPF treatment, nerandomilast. With a strong clinical background and a passion for advancing therapies for fibrotic lung diseases, she played a key role in the successful development and launch of OFEV across four indications. A respected leader and scientific partner in the pulmonology field, she brings deep expertise in trial strategy, regulatory interactions, and cross-functional collaboration to drive meaningful patient outcomes.
Seminars
Wednesday 20th August 2025
Nerandomilast as a New Benchmark in Pulmonary Fibrosis: Lessons Learned from the Clinical Development Program
8:30 am
- How did the preclinical and translational data inform the design of the phase II and phase III trials? What were the key trial design features, patient populations, endpoints, and readouts that contributed to the successful outcome?
- How were the insights from both preclinical and clinical stages integrated into a cohesive development strategy that led to a positive phase III readout? What can we learn for future trials in IPF?
